Literature DB >> 22170105

Production, characterisation and immunogenicity of a plant-made Plasmodium antigen--the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1.

Charles Ma1, Lina Wang, Diane E Webster, Alison E Campbell, Ross L Coppel.   

Abstract

Development of a safe, effective and affordable malaria vaccine is central to global disease control efforts. One of the most highly regarded proteins for inclusion in an asexual blood stage subunit vaccine is the 19-kDa C-terminal fragment of merozoite surface protein 1 (MSP1(19)). As production of vaccine antigens in plants can potentially overcome cost and delivery hurdles, we set out to produce MSP1(19) in plants, characterise the protein and test its immunogenicity using a mouse model. Plasmodium yoelii MSP1(19) (PyMSP1(19)) was produced in Nicotiana benthamiana using the MagnICON® deconstructed TMV-based viral vector. PyMSP1(19) yield of at least 23% total soluble protein (TSP;3-4 mg/g Fwt) were achieved using a codon-optimised construct that was targeted to the apoplast. Freeze-dried leaf powder contained at least 20 mg PyMSP1(19) per gram dry weight and the protein retained immunogenicity in this form for more than 2 years. Characterisation studies, including SDS-PAGE, mass spectrometry and circular dichroism, indicated that the plant-expressed PyMSP1(19) was similar to its Escherichia coli- and Saccharomyces cerevisiae-expressed counterparts. Purified plant-made PyMSP1(19) induced strong immune responses following intraperitoneal immunisation, although titres were lower than those induced by an equivalent dose of purified E. coli-expressed PyMSP1(19). The reason for this is uncertain but may be due to differences in the oligomerisation profile of the vaccines. The plant-made PyMSP1(19) vaccine was also found to be orally immunogenic when delivered alone or following immunisation with a PyMSP1(19) DNA vaccine. This study adds to an increasing body of research supporting the feasibility of plants as both a factory for the production of malaria antigens, and as a safe and affordable platform for oral delivery of a temperature-stable malaria vaccine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22170105     DOI: 10.1007/s00253-011-3772-7

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  5 in total

1.  Plant expression and characterization of the transmission-blocking vaccine candidate PfGAP50.

Authors:  Veronique Beiss; Holger Spiegel; Alexander Boes; Matthias Scheuermayer; Andreas Reimann; Stefan Schillberg; Rainer Fischer
Journal:  BMC Biotechnol       Date:  2015-12-01       Impact factor: 2.563

Review 2.  Overview of plant-made vaccine antigens against malaria.

Authors:  Marina Clemente; Mariana G Corigliano
Journal:  J Biomed Biotechnol       Date:  2012-07-15

Review 3.  The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B.

Authors:  Young Hee Joung; Se Hee Park; Ki-Beom Moon; Jae-Heung Jeon; Hye-Sun Cho; Hyun-Soon Kim
Journal:  Int J Mol Sci       Date:  2016-10-13       Impact factor: 5.923

Review 4.  Plant-based oral vaccines against zoonotic and non-zoonotic diseases.

Authors:  Naila Shahid; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2016-08-23       Impact factor: 9.803

Review 5.  Virus-based pharmaceutical production in plants: an opportunity to reduce health problems in Africa.

Authors:  Pingdwende Kader Aziz Bamogo; Christophe Brugidou; Drissa Sérémé; Fidèle Tiendrébéogo; Florencia Wendkuuni Djigma; Jacques Simpore; Séverine Lacombe
Journal:  Virol J       Date:  2019-12-30       Impact factor: 4.099

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.